TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02993484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Malonate
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Malonate
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemia reperfusion
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemia reperfusion
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
Study: NCT00523042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT05032079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: single probe ultrasound guided cryoablation
Study: NCT04223830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exalt Model D Single-Use Duodenoscope
Description: Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
Study: NCT03291704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal therapy device
Description: Thermal therapy of blocked Meibomian glands
Study: NCT00931554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative drain removal
Description: removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative drain removal
Description: removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
Study: NCT01822977

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: omeprazole
Study: NCT02652143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AneVivo (Medical device for in vivo culture of embryos)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comparator for embryo culture in vitro
Study: NCT02877160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794 tablet
Study: NCT03484520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: intravenous
Study: NCT00524719

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction and Internal Fixation
Description: Fixation with volar locked plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Spanning External Fixation
Description: Radio-radial external fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Reduction with Percutaneous Fixation
Description: Percutaneous intrafocal pinning (Kapandji technique)
Study: NCT01995877

Intervention type: PROCEDURE
Intervention: Subjects scheduled for IVC filter placement
Description: Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure.
Study: NCT02685943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Study: NCT04209621

Intervention type: DRUG
Group type: OTHER
Intervention: Duvelisib
Description: twice daily as tolerated until disease progression

Intervention type: DRUG
Group type: OTHER
Intervention: Ibrutinib
Description: daily for the first six 28-day cycles
Study: NCT04139798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.6% sodium chloride solution)
Study: NCT04100850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercises
Description: twice a week, lasting 50 minutes, for two months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watsu
Description: twice a week, lasting 50 minutes, for two months.
Study: NCT02223403

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice
Description: 3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice
Description: 3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-deplete beetroot juice
Description: 3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-deplete beetroot juice
Description: 3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
Study: NCT05406804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation
Description: 1) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time \> 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
Study: NCT02962544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FS-SMILE
Description: The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FS- LASIK
Description: LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visumax device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS 200 device
Study: NCT02147665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hookah smoking
Description: Subjects will smoke waterpipe in a controlled research environment.
Study: NCT04395703

Intervention type: OTHER
Intervention: Interviews and focus groups
Description: Unstructured and semi-structured interviews with open ended questions.

Intervention type: OTHER
Intervention: Interviews and focus groups
Description: Unstructured and semi-structured interviews with open ended questions.
Study: NCT01543724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 10mg/kg/day for 12 weeks
Study: NCT02271997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous gluconate
Description: treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron(III)carboxymaltose
Description: treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Study: NCT01067326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150 mg Aliskiren once daily for a period of 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per day by mouth for 4 months
Study: NCT01230788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
Study: NCT01610362

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rabies Immune Globulin
Description: HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rabies Immune Globulin
Description: HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
Study: NCT01740323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 mg BID
Study: NCT04743154

Intervention type: OTHER
Group type: OTHER
Intervention: In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)
Description: To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.

Intervention type: OTHER
Group type: OTHER
Intervention: After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)
Description: To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
Study: NCT00751842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270.
Study: NCT02182570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL 801 CL dry syrup
Study: NCT00969046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (patupilone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (patupilone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (patupilone)
Study: NCT02393274

Intervention type: DEVICE
Intervention: Extra-corporeal membrane oxygenation life support
Description: venoarterial extra-corporeal membrane oxygenation life support

Intervention type: DEVICE
Intervention: Extra-corporeal membrane oxygenation life support
Description: venoarterial extra-corporeal membrane oxygenation life support
Study: NCT03047759

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water flosser
Description: Powered

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: air floss
Description: Powered
Study: NCT02626754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
Study: NCT03181451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Maltol
Description: To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Maltol
Description: To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Maltol
Description: To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
Study: NCT02141789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient Cognitive Behavioral Psychotherapy
Description: Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient Cognitive Behavioral Psychotherapy
Description: The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
Study: NCT01937325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivacaftor
Description: active arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: active arm
Study: NCT04030507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
Study: NCT01695915

Intervention type: PROCEDURE
Intervention: Transabdominal ultrasound
Description: Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.

Intervention type: PROCEDURE
Intervention: Transabdominal ultrasound
Description: Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
Study: NCT02042196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUVAN
Description: KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUVAN
Description: KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUVAN
Description: KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pills designed to match the dissolvable KUVAN pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pills designed to match the dissolvable KUVAN pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pills designed to match the dissolvable KUVAN pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide
Description: Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide
Description: Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Climara
Description: 0.075mg/d transdermal patch will be placed on skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo transdermal patch
Description: Inactive transdermal patch
Study: NCT04384848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPATHY Pilot
Description: The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
Study: NCT02196714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1
Description: Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
Study: NCT02196714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium and Formoterol Fumarate (GFF) Dose 2
Description: Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (GP) Dose 1
Description: Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (GP) Dose 2
Description: Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
Study: NCT04615767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: as described previously
Study: NCT01185925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil, 50 mg 3 times/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo